Docexan 80 mg/vial (IV Infusion)
80 mg vial: ৳ 13,900.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Docetaxel trihydrate |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Product Title
Docexan
Categories
- Medical Supplies
- Cancer Treatment
- Chemotherapy
- Oncology
Description
Docexan is a microtubule inhibitor indicated for treating Breast Cancer, Non-small Cell Lung Cancer, Castration-Resistant Prostate Cancer, Gastric Adenocarcinoma, and Squamous Cell Carcinoma of the Head and Neck.
Color Options
- Clear
Dimensions
N/A
Materials
- Docetaxel
Technical Specifications
- Dosage Administration: Administer intravenously (IV) over 1 hr every 3 weeks
- Dosage Range:
- 60 mg/m^2 to 100 mg/m^2 single agent for Breast Cancer
- 75 mg/m^2 single agent for Non-small Cell Lung Cancer (NSCLC)
- 75 mg/m^2 with prednisone for Castration-Resistant Prostate Cancer
- 75 mg/m^2 followed by cisplatin and fluorouracil for Gastric Adenocarcinoma (GC)
- 75 mg/m^2 followed by cisplatin and fluorouracil for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Interaction: Docexan is a CYP3A4 substrate, and its metabolism may be modified by certain compounds
- Contraindications: Contraindicated in patients with neutrophil counts of <1500 cells/mm^3 and severe hypersensitivity reactions to docetaxel or polysorbate 80
- Side Effects: Common adverse reactions include infections, neutropenia, anemia, febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, and more
- Pregnancy & Lactation: Can cause fetal harm when administered to a pregnant woman; no information on its presence in human milk or effects on the breastfed child
- Precautions & Warnings: Docexan should be administered under the supervision of a physician experienced in the use of antineoplastic agents; higher risk of severe adverse reactions in patients with hepatic impairment; should not be given to patients with neutrophil counts of less than 1,500 cells/mm^3
- Overdose Effects: No known antidote for docetaxel overdose; primary anticipated complications consist of bone marrow suppression, peripheral neurotoxicity, and mucositis
- Therapeutic Class: Cytotoxic Chemotherapy
- Storage Conditions: Store between 2°C and 25°C and protected from light; freezing does not adversely affect the product
Usability Features
- To be administered in a facility equipped to manage possible complications
- Use only a 21 gauge needle to withdraw docetaxel from the vial
- Premedicate with oral corticosteroids; adjust dose as needed
Design Elements
- Pharmacology: Acts by disrupting the microtubular network in cells that is essential for vital mitotic and interphase cellular functions
- Mode of Action: Promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly; cytotoxic against various tumor cell lines